Product Description
Mechanisms of Action: GR Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Brazil | Bulgaria | Chile | Croatia | Denmark | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Latvia | Lithuania | Malta | Morocco | New Zealand | Pakistan | Peru | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Sweden | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: ISTITUTO NAZIONALE PER LA CURA TUMORI
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Calendula versus placebo/cortisone in prevention of radiotherapy-induced erythema | P2 |
Active, not recruiting |
Breast Cancer |
2009-07-18 |